Impact of a Meds-to-Beds PCSK9i Initiation Program on Low-density Lipoprotein Cholesterol (LDL-C) in Patients Undergoing ASCVD Revascularization
Authors' conclusion
Early initiation of guideline-recommended PCSK9i mAbs through a dedicated M2B program was associated with enhanced attainment of LDL-C goals in patients with established atherosclerotic cardiovascular disease undergoing revascularization.
Study context
- Population
- Patients undergoing coronary or peripheral artery revascularization, on maximally tolerated statin therapy, and with LDL-C ≥70 mg/dL
- Participants
- 72 vs 136
- Exposure
- LDL-C goal attainment rates were compared with standard of care using a direct-matched retrospective cohort
- PCSK9i mAb groupn = 72
- Control groupn = 136
- Outcome
- Baseline median LDL-C
- Follow-up
- Baseline
Methodological detailsdedicated meds-to-beds (M2B) program, historical controls
- Dedicated M2B program
- Historical controls
Main finding
As reported in the abstract
P < 0.05
Observational data: associations, not effects.
Further findings
LDL-C goal achievement · 6 months · for both goals; greater in the PCSK9i mAb group
P < 0.001
LDL-C <70 mg/dL
LDL-C <55 mg/dL
Median percent reduction
| Outcome | PCSK9i mAb group | Control group | P value |
|---|---|---|---|
| Median percent reduction in LDL-CLarger in the PCSK9i mAb group | 66% | 25% | P < 0.001 |
Prospective cohort characteristics
- Median age
- 66 years
- Women
- 38%
- Hispanic
- 57%
Original publication
Impact of a Meds-to-Beds PCSK9i Initiation Program on LDL-C in Patients Undergoing ASCVD Revascularization. JACC Adv. Published 19 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →